A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
Key claim: An early-phase clinical trial is evaluating the safety and optimal dosing of rebecsinib, a novel investigational drug, in patients with relapsed/refractory secondary AML or high-risk myelofibrosis.
Abstract
The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either Secondary Acute Myeloid Leukemia (sAML) that has either returned (relapsed) or not responded to treatment (refractory) or have higher risk Myelofibrosis (MF). Participants will receive a study drug infusion on Day 1, Day 4, Day 8 and Day 11 of each 28-day cycle for a total of 6 cycles.
Why this matters
Rebecsinib enters the crowded pipeline of investigational agents being tested in high-risk MF and post-MPN sAML, where treatment options after JAK inhibitor failure remain limited. Establishing safety and dosing in this first-in-class clinical evaluation is the prerequisite step before efficacy and mechanism can be benchmarked against other novel agents in this space.